• Financial performance: In Q4, revenue rose 4% year-on-year and PAT grew 29% to ₹200 crore, while full-year revenue expanded 10% to ₹7,345 crore across all geographic territories and API segments.
• R&D expenditure: Q4 R&D spend rose to 11% of revenue to total ₹700 crore for the year due to one-off peptide NC-1 filings, with recurring R&D expected to normalize around 9% of revenue.
• US branded expansion: Alembic launched its first branded US product, Pivya, through Alembic Therapeutics with a 30-person sales force, anticipating revenue pickup over coming quarters alongside additional in-licensing deals.
• Revenue growth outlook: The company targets at least 10% overall top-line growth, driven by 10–15% growth in the US, over 15% in rest-of-the-world markets, and high single-digit to 10% growth in the API business.
• Facility utilization: The WHO-certified Indore facility is operating at 40–50% capacity utilization following product transfers from Sikkim, while rising utilization across injectables, oncology, and ophthalmics facilities is expected to support margin expansion.